Maryland Remicade Attorneys

Remicade (also known as Infliximab), is manufactured by the Johnson & Johnson subsidiary, Centocor. Remicade is used to treat Crohn's Disease and Rheumatoid Arthritis. Remicade was first approved by the FDA on August 24, 1998. Remicade was specifically approved for Rheumatoid Arthritis on November 10, 1999. Remicade is made from a combination of mouse and human substances and is administered intravenously, at a doctor's office or hospital. The patient is given 3 mg/kg as a single dose. The initial dose should be followed by additional 3 mg/kg doses two and six weeks after the first dose. The maintenance dose is 3 mg/kg every eight weeks. Patients often take Methotrexate simultaneously with Remicade treatments. Our Maryland Remicade Attorneys can assist you if you have been injured by taking Remicade.

Have you or someone you know suffered injuries due to taking Remicade? If so, contact our Maryland Remicade Attorneys today!

Tumor necrosis factor (TNF) plays a key role in the response of the body's immune system to infections. The action of blocking TNF may worsen or increase the occurrence of infections. Remicade blocks the effects of TNF-alpha.

A "black box warning" is the strongest available to drug manufacturers. On August 15, 2001, Centocor announced that a "black box warning" was being added to Remicade's label in order to better inform doctors and patients of the increased chance of developing tuberculosis while receiving Remicade treatments. This increased warning followed allegations that Remicade has been associated with 84 cases of tuberculosis and at least 14 deaths.

Remicade, a drug used to treat rheumatoid arthritis and Crohn’s disease, has been associated with potentially fatal blood disorders and infections, including tuberculosis.

A warning about the use of Remicade was issued by the Food and Drug Administration and the drug’s manufacturer, Centocor, a subsidiary of Johnson & Johnson, in August 2004. At that time there had been 580 reports of adverse reactions, including 12 deaths.

A letter was sent that same month to doctors alerting them that patients using Remicade have suffered reductions in blood and platelet counts that left them more susceptible to abnormal bleeding and infections, including invasive fungal infections and an increased chance of developing tuberculosis. Some patients also suffered central nervous system disorders, including those leading to a swelling and decay of blood vessels. Our Maryland Remicade Attorneys can help you win the compensation you deserve.

Remicade, whose active ingredient is infliximab, was introduced in the United States in 1998.

Have you or someone you know suffered injuries due to taking Remicade? If so, contact our Maryland Remicade Attorneys today!